Agenus signs USD141M partnership with Zydus Lifesciences to advance cancer immunotherapy program

USA—Agenus has finalised a strategic collaboration worth USD141 million with Zydus Lifesciences, marking a significant step forward in the global development and potential commercialisation of its innovative cancer treatment combination.

The partnership centres on botensilimab and balstilimab, commonly referred to as BOT/BAL, which represents a promising immunotherapy approach for treating difficult-to-treat cancers.

This collaboration delivers crucial funding to Agenus while simultaneously securing sustained biologics manufacturing capacity within the United States.

The arrangement supports multiple critical objectives, including ongoing clinical development activities, early access initiatives that bring the treatment to patients sooner, and establishing infrastructure for future commercial production at scale.

The agreement grants Zydus exclusive rights to develop and commercialise the BOT/BAL combination across India and Sri Lanka.

In exchange for these regional rights, Agenus will receive a 5% royalty on all net sales generated from these markets, creating an ongoing revenue stream as the therapy reaches patients in South Asia.

The financial structure of this partnership includes several substantial components that strengthen Agenus’s position.

 Zydus has provided a USD75 million upfront cash payment to Agenus, which covers the transfer of manufacturing facilities located in Emeryville and Berkeley, California.

Additionally, Zydus has made a USD16 million equity investment in Agenus, acquiring approximately 2.1 million shares of common stock at USD7.50 per share.

The deal also includes up to USD50 million in contingent milestone payments, which Zydus will trigger through production orders of the BOT/BAL combination.

Clinical trial results have demonstrated the potential effectiveness of this immunotherapy combination in treating particularly challenging cancer cases.

In an expanded cohort involving 123 patients with third-line or later microsatellite-stable metastatic colorectal cancer without active liver metastases, the BOT/BAL combination achieved a two-year overall survival rate of 42%.

Furthermore, the treatment demonstrated a mature median overall survival of 21 months, representing encouraging outcomes for patients facing limited treatment options.

Agenus has launched the global BATTMAN Phase III trial in collaboration with the Canadian Cancer Trials Group, with sites now activated and actively enrolling patients.

This large-scale study will provide additional data to support potential regulatory approvals across multiple markets.

Following the completion of this transaction, the manufacturing facilities in Emeryville and Berkeley will transfer to Zydus ownership under its newly established subsidiary, Zylidac Bio.

However, Agenus has secured committed manufacturing capacity at these same US sites, ensuring continued production capabilities for global access programmes, commercialisation activities, and ongoing clinical trials.

Throughout the partnership development process, Agenus received strategic advisory support from Porrima and Biotech Value Advisors.

These firms provided guidance on partner selection, transaction structuring, and negotiation strategies that helped shape the final agreement.

Dr Garo Armen, who serves as chairman and CEO of Agenus, highlighted the transformative impact of this collaboration.

He emphasised that closing this partnership strengthens the company’s balance sheet while securing dedicated US manufacturing capacity at a pivotal moment in the company’s development.

Dr Armen outlined the company’s priorities for 2026, which include disciplined execution across operations, advancing the Phase III programme, broadening paid patient access through authorised pathways, and progressing toward regulatory submission.

He noted that this submission will be supported by one of the most substantial clinical datasets ever generated in microsatellite-stable colorectal cancer research.